MEDNAX (MD) Releases Q1 Earnings Guidance

MEDNAX (NYSE:MD) updated its first quarter earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.84-0.89 for the period, compared to the Thomson Reuters consensus estimate of $0.79.

Several equities analysts recently commented on the stock. Robert W. Baird upped their price target on shares of MEDNAX from $48.00 to $54.00 and gave the company a neutral rating in a report on Friday. Mizuho set a $53.00 price target on shares of MEDNAX and gave the company a hold rating in a report on Friday. Jefferies Group set a $50.00 price target on shares of MEDNAX and gave the company a hold rating in a report on Tuesday. Stephens set a $62.00 price target on shares of MEDNAX and gave the company a buy rating in a report on Thursday. Finally, Citigroup cut their price target on shares of MEDNAX from $52.00 to $47.00 and set a neutral rating on the stock in a report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $55.08.

Shares of MEDNAX (NYSE MD) opened at $53.94 on Friday. The stock has a market cap of $4,922.52, a PE ratio of 15.63, a price-to-earnings-growth ratio of 1.45 and a beta of 0.31. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.43 and a quick ratio of 1.37. MEDNAX has a 52-week low of $40.56 and a 52-week high of $72.13.

MEDNAX (NYSE:MD) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.04. The company had revenue of $910.82 million during the quarter, compared to analysts’ expectations of $884.55 million. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.00 EPS. equities research analysts anticipate that MEDNAX will post 3.62 earnings per share for the current year.

In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply